HOME >> MEDICINE >> NEWS
Trial shows malaria vaccine could protect young children from disease for 18 months

The RTS, S/AS02A vaccine could protect young African children against a range of clinical disease caused by the malaria parasite for at least 18 months, concludes a randomised trial published online today (Tuesday November 15, 2005) by The Lancet.

Early trials of the RTS, S/AS02A vaccine have shown that the vaccine is safe, well tolerated, and can trigger an immune response. In one of the trials, involving over 2000 Mozambican children aged 1-4 years, Pedro Alonso (University of Barcelona, Spain) and colleagues found that after 6 months' follow-up the vaccine reduced the risk of clinical malaria by 30%, delayed time to first infection by 45%, and reduced the risk of severe malaria by 58%. In the latest study the investigators followed-up the children for a further 12 months. They found that the efficacy of the drug did not wane and that protection against clinical malaria lasted for at least 18 months after vaccination. The study shows that the vaccine reduces the risk of clinical malaria by 35% and nearly halves the risk of severe malaria over a period of 18 months.

Professor Alonso states: "Our results show that the RTS,S/AS02A candidate malaria vaccine confers partial protection for at least 18 months against a range of clinical diseases caused by P falciparum in children living in a rural malaria endemic area of African The combination of sustained protection together with substantial prevention of the severe forms of malaria marks RTS, S/AS02A as a promising vaccine candidate and strongly suggests that malaria vaccines have an important role as future public-health instruments."

The publication coincides with a presentation at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference 2005 in Yaounde, Cameroon.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
15-Nov-2005


Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows vaccine against cervical cancer provides long-term protection
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... common plastics, chemical during pregnancy may have effects on genital ... found that baby boys born to moms with greater exposure ... anogenital distance -- the space between the genitals and anus. ... a marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... (HealthDay News) -- Eating a low-carb, high-fat diet could ... to new research. A review of five ... that focuses on foods like bacon, eggs, heavy cream, ... in adults whose condition doesn,t improve with medication. ... people with epilepsy whose seizures are not stopped by ...
(Date:10/30/2014)... care respects the fact that a patient,s body ... treatment. Over a third of cancer patients experience ... their conditions. And, increasingly, care providers are exploring ... navigate mental health challenges. A University of Colorado ... Psycho-Oncology asks an important question: after ...
(Date:10/29/2014)... – Many of the women at first acted surprised. Some ... researchers why they had not used the study products assigned ... trial that, as a likely consequence, did not find any ... , The women were among 127 former VOICE participants ... agreed to take part in in-depth interviews and/or focus group ...
(Date:10/28/2014)... the inner and outer body and organ surfaces in ... pancreas and in the inner ear," said Moritz Gegg. ... BBs and are precisely positioned on many of these ... movements be coordinated so precisely that for example mucus ... be perceived from sensory inner ear hair cells," added ...
Breaking Medicine News(10 mins):Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3Health News:New insights into the development of ciliopathies 2
(Date:10/30/2014)... 2014 Boston Scientific Corporation (NYSE: ... Credit Suisse Annual Healthcare Conference on Tuesday, November 11, ... Dan Brennan , executive vice president and chief financial ... at approximately 8:00 a.m. PT followed by a question ... the presentation and question and answer session will be ...
(Date:10/30/2014)... ANGELES , Oct. 30, 2014   ... company devoted to bringing new products to market, ... drug called TetraStem. TetraStem is a topical liquid ... delivery system that can convert oral medication active ... registered as a first aid antibiotic to help ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
Cached News: